AGP Executive Report
Last update: 11 hours agoRegulation & Access: Cambodia’s PM Hun Manet reiterated a hard line against cannabis cultivation and also rejected e-cigarette/vape production investment, citing control and youth public-health risks. Clinical Safety: UK data show nearly 2 million unlicensed medical cannabis items were prescribed privately in England over a year, prompting warnings about patient harm and online purchasing. Science & Risk: Researchers identified brain cells linked to cannabinoid-triggered anxiety in stressful settings, helping explain why some “good trips” turn scary. Policy & Youth: A Caribbean Senate debate over raising alcohol/tobacco/vaping and cannabis ages to 21/25 highlighted fears that edible-style products can expose young people to harm. Market Moves: Avecho says its CBD sleep capsule Phase III insomnia trial is progressing toward full enrolment and plans regulator talks in the US and Europe; Elixinol agreed to buy supplement platform Vitable to boost recurring wellness revenue. Corporate/Deal Watch: Curaleaf filed an updated offer for Aurora and urged shareholders to take no action pending review. Legal/Enforcement: Michigan’s court backed action against a marijuana farm for violating protected wetlands.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
